Paul Song

Dr. Song has nearly 25 years of experience as a clinician and translational medicine expert. He is currently Co-founder and CEO at FuseBio Therapeutics. Prior to FuseBio he was Chief Medical Officer at NKMax America and, before that, at Cynvenio Biosystems. In addition Dr. Song, was an attending physician at the Samuel Oschin Cancer Center at Cedars-Sinai Medical Center and previously served as CMO/Senior Advisor for Berg Health.

Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from The George Washington University. He completed his residency in radiation oncology at the University of Chicago where he served as Chief Resident and did a brachytherapy fellowship at the Institute Gustave Roussy in Villejuif, France. He was also awarded an ASTRO research fellowship for his research in radiation inducible gene therapy. Dr. Song is a board certified Radiation Oncologist with expertise in translational medicine, clinical trials, and therapeutic development within oncology and immunology